Tralokinumab: New treatment for atopic dermatitis

The human monoclonal antibody tralokinumab, specifically neutralizing interleukin-13, shows promising efficacy and safety in patients with atopic dermatitis in just 16 weeks. Let Professor of Dermatology Steve Feldman guide you through his take on the therapeutic potential of tralokinumab in the treatment of atopic dermatitis.